# Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

> **NCT02700048** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Minnesota** · enrollment: 11 (actual)

## Conditions studied

- Hypoglycemia Unawareness
- Type 1 Diabetes

## Interventions

- **DRUG:** intra-nasal naloxone
- **DRUG:** Intra-nasal saline

## Key facts

- **NCT ID:** NCT02700048
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2021-07
- **Final completion:** 2021-07
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** research grant for the trial was not funded
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02700048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02700048, "Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02700048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*